Novartis has announced that phase 3 clinical trials data published in the Lancet showed significant benefit of its cancer drug, Afinitor (everolimus) in patients with non-cancerous tumours ...

In final draft guidance, NICE said an updated cost-effectiveness analysis had convinced it that Novartis' Afinitor (everolimus) daily pill in combination with exemestane (Pfizer's off-patent ...

US biotech Exelixis (Nasdaq: EXEL) has secured a sixth indication for its cancer drug Cabometyx (cabozantinib), following a green light from the Food and Drug Administration for advanced ...

The drug is a generic version of AFINITOR DISPERZ by Novartis Pharmaceutical Corporation, it added. "NATCO's marketing partner for the ANDA, Breckenridge Pharmaceutical, Inc plans to launch the ...